Cabozantinib for radioiodine-refractory differentiated thyroid cancer
Prof. Marcia Brose
The multinational phase 3 COSMIC-311 study randomized patients with radioiodine-refractory differentiated thyroid cancer who had no available standard of care to cabozantinib or placebo. The ORR was 15% in the cabozantinib group versus 0% in the placebo group. The median PFS was not reached in the cabozantinib group versus 1.9 months in the placebo group (HR 0.22; p<0.0001). The authors conclude that cabozantinib might provide a new treatment option for this patient population.
